SCHEMBL5016286

SCHEMBL5016286

Clc1cc(-c2ccco2)nc(-c2ccccn2)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.66
ALDH1A1 P00352 4/20 0.66
RAB9A P51151 4/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
TP53 P04637 4/20 0.57
PKM P14618 3/20 0.57
NPC1 O15118 3/20 0.57
HSD17B10 Q99714 2/20 0.57
POLB P06746 2/20 0.57
MAPT P10636 4/20 0.54
GFER P55789 1/20 0.54
KDM4C Q9H3R0 1/20 0.54
TDP1 Q9NUW8 2/20 0.49
CYP19A1 P11511 1/20 0.46
GRM5 P41594 5/20 0.45
TSHR P16473 2/20 0.45
MEN1 O00255 1/20 0.45
GLA P06280 1/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5016195 0.82 KDM4E (0.66) KDM4EALDH1A1RAB9ASMN1; SMN2TP53
SCHEMBL5022387 0.82 KDM4E (0.66) KDM4EALDH1A1RAB9ASMN1; SMN2TP53
SCHEMBL29545764 0.81 CCR1 (0.63) KDM4EALDH1A1RAB9ASMN1; SMN2TP53
SCHEMBL4490247 0.81 CCR1 (0.63) KDM4EALDH1A1RAB9ASMN1; SMN2TP53
SCHEMBL1442585 0.81 TDP1 (0.68) KDM4ERAB9ASMN1; SMN2TP53PKM
SCHEMBL30423972 0.81 TDP1 (0.68) KDM4ERAB9ASMN1; SMN2TP53PKM
SCHEMBL29836037 0.79 KDM4E (0.73) KDM4EALDH1A1RAB9ASMN1; SMN2TP53
SCHEMBL731598 0.79 KDM4E (0.73) KDM4EALDH1A1RAB9ASMN1; SMN2TP53
SCHEMBL5016163 0.78 SMN1; SMN2 (0.54) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL9487125 0.76 KDM4E (0.57) KDM4EALDH1A1RAB9ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
CN-1953975-A 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists ALMIRALL PRODESFARMA AG (CH) 2007-04-25 CN disclosed
EP-1697351-A1 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma AG (CH) 2006-09-06 EP disclosed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 KDM4E 3504/4885ALDH1A1 408/4885RAB9A 942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.